A binding site model of membrane transport: Binary and cooperative flows

1979 ◽  
Vol 50 (3-4) ◽  
pp. 205-224
Author(s):  
M. Howard Lee ◽  
A. Nihat Berker ◽  
H. Eugene Stanley ◽  
Alvin Essig
Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 1013-1013
Author(s):  
Evgeny M. Makogonenko ◽  
Andrey G. Sarafanov ◽  
Natalya M. Ananyeva ◽  
Dudley K. Strickland ◽  
Evgueni L. Saenko

Abstract Clearance of coagulation factor VIII (fVIII) is mediated by a hepatic receptor low-density lipoprotein receptor-related protein (LRP), a member of low-density lipoprotein receptor (LDLR) family. It has been recently discovered that LDLR acts in concert with LRP in regulating fVIII level. FVIII has the domain structure A1-A2-B-A3-C1-C2, and to identify the portions providing the interaction with LDLR, in surface plasmon resonance-based assay we studied the binding of fVIII and its fragments to immobilized recombinant ligand-binding domain of LDLR (residues 1-292). The affinity values were determined from the families of binding signals obtained for five concentrations (10–150 nM) of each analyte. The binding signals for full-length fVIII, and its portions A3-C1–C2 (or light chain, LCh) and A1/A3-C1–C2 heterodimer (derived from activated fVIII) were best fitted to a two-site model, with equilibrium dissociation constants KD(1) ~1, 4, 14 nM and KD(2) ~14, 45 and 37 nM, respectively. Noteworthy, we did not observe any significant binding for the isolated C2 domain (at 300 nM). This suggests that the LDLR-binding site within LCh is likely located within the A3 domain, similar to that found previously for LCh-LRP interaction. The binding signals for A1-A2-B (heavy chain, HCh) were best fitted to a one-site model, with KD ~60 nM. We registered a dose-dependent, high-affinity binding of the isolated A2 domain to LDLR, with KD ~14 nM whereas the A1 domain showed no appreciable binding. This suggests that within HCh, A2 domain bears the LDLR-binding site. Von Willebrand factor did not significantly block the binding of fVIII to LDLR as compared to a 3-fold inhibition of fVIII binding to LRP. This indicates that within fVIII/vWf complex, the A2 binding site for LDLR is more available than that for LRP. Anti-A2 monoclonal antibody 413 (epitope 484–509) inhibited the A2 binding to LDLR in a dose-dependent manner, similarly to that demonstrated for fVIII-LRP interaction. A number of A2 point mutants with substitutions of the residues critical for A2 binding to LRP, megalin and VLDL were found to have significantly reduced affinity also for LDLR. The obtained data indicate that fVIII interacts with LDLR preferentially via the binding sites located within the A2 domain of HCh and within the A3 domain of LCh, and that the A2 site is likely to be universal for the interactions with four tested members of LDL receptor family.


2013 ◽  
Vol 104 (12) ◽  
pp. 2751-2763 ◽  
Author(s):  
Markus Dittrich ◽  
John M. Pattillo ◽  
J. Darwin King ◽  
Soyoun Cho ◽  
Joel R. Stiles ◽  
...  

1991 ◽  
Vol 274 (3) ◽  
pp. 861-867 ◽  
Author(s):  
R A J Challiss ◽  
A L Willcocks ◽  
B Mulloy ◽  
B V L Potter ◽  
S R Nahorski

1. The properties of specific Ins(1,4,5)P3- and Ins(1,3,4,5)P4-binding sites have been compared in a crude ‘P2’ cerebellar membrane fraction. 2. A homogeneous population of [3H]Ins(1,4,5)P3-binding sites was present (KD 23.1 +/- 3.6 nM) at high density (Bmax. 11.9 +/- 1.8 pmol/mg of protein); whereas data obtained for [32P]Ins(1,3,4,5)P4 specific binding were best fitted to a two-site model, the high-affinity binding component (KD 2.6 +/- 0.7 nM) constituted 64.2 +/- 4.3% of the total population and was present at relatively low density (Bmax. 187 +/- 27 fmol/mg of protein). 3. The two high-affinity inositol polyphosphate-binding sites exhibited markedly different pH optima for radioligand binding, allowing the two sites to be independently investigated. At pH 8.0, [3H]Ins(1,4,5)P3 binding was maximal, whereas [32P]Ins(1,3,4,5)P4 specific binding was very low; conversely, at pH 5.0, [32P]Ins(1,3,4,5)P4 binding was maximal, whereas [3H]Ins(1,4,5)P3 binding was undetectably low. 4. Both inositol polyphosphate-binding sites exhibited marked positional and stereo-specificity. Of the analogues studied, only phosphorothioate substitution to form inositol 1,4,5-trisphosphorothioate was tolerated at the Ins(1,4,5)P3-binding site, with only a 2-3-fold loss of binding activity. Addition of a glyceroyl moiety at the 1-phosphate position or addition of further phosphate substituents at the 3- or 6-positions caused dramatic losses in displacing activity. Similarly, complete phosphorothioate substitution of Ins(1,3,4,5)P4 caused an approx. 6-fold loss of binding activity at the [32P]Ins(1,3,4,5)P4-binding site, whereas Ins(1,4,5,6)P4, Ins(1,3,4,6)P4, Ins(1,4,5)P3 and Ins(1,3,4,5,6)P5 were bound at least 100-fold weaker at this site. Therefore, only the phosphorothioate derivatives retained high affinity and selectivity for the two inositol polyphosphate-binding sites. 5. Heparin and pentosan polysulphate were potent but non-selective inhibitors at Ins(1,4,5)P3- and Ins(1,3,4,5)P4-binding sites. N-Desulphation (with or without N-reacetylation) of heparin decreased inhibitory activity at the Ins(1,4,5)P3-, but not at the Ins(1,3,4,5)P4-binding site; however, the selectivity of this effect was only about 4-fold. O- and N-desulphated N-reacetylated heparin was essentially inactive at both sites. 6. The results are discussed with respect to the separate identities of the inositol polyphosphate-binding sites.


2013 ◽  
Vol 45 ◽  
pp. 26-37 ◽  
Author(s):  
Rodrigo Aguayo-Ortiz ◽  
Oscar Méndez-Lucio ◽  
Antonio Romo-Mancillas ◽  
Rafael Castillo ◽  
Lilián Yépez-Mulia ◽  
...  

1986 ◽  
pp. 783-788
Author(s):  
Josef Koehrle ◽  
Michael Auf’mkolk ◽  
Matthias Spanka ◽  
Vivian Cody ◽  
Rolf-Dieter Hesch

Author(s):  
Emmanuel E. Polymeropoulos ◽  
Norbert Höfgen
Keyword(s):  

2012 ◽  
Vol 2012 ◽  
pp. 1-14 ◽  
Author(s):  
W. S. Cuello ◽  
T. A. T. Janes ◽  
J. M. Jessee ◽  
M. A. Venecek ◽  
M. E. Sawyer ◽  
...  

Bromochloromethane (BCM) is a volatile compound and a by-product of disinfection of water by chlorination. Physiologically based pharmacokinetic (PBPK) models are used in risk assessment applications. An updated PBPK model for BCM is generated and applied to hypotheses testing calibrated using vapor uptake data. The two different metabolic hypotheses examined are (1) a two-pathway model using both CYP2E1 and glutathione transferase enzymes and (2) a two-binding site model where metabolism can occur on one enzyme, CYP2E1. Our computer simulations show that both hypotheses describe the experimental data in a similar manner. The two pathway results were comparable to previously reported values (Vmax=3.8 mg/hour,Km=0.35 mg/liter, andkGST=4.7 /hour). The two binding site results wereVmax⁡1=3.7 mg/hour,Km⁡1=0.3 mg/hour, CL2= 0.047 liter/hour. In addition, we explore the sensitivity of different parameters for each model using our obtained optimized values.


2004 ◽  
Vol 18 (12) ◽  
pp. 785-796 ◽  
Author(s):  
Viktor Kettmann ◽  
Daniela Košt’álová ◽  
Hans-Dieter Höltje

Sign in / Sign up

Export Citation Format

Share Document